stockrow
Friday 6 November 2026
Export RNLXY’s income statement to Excel — free account
Renalytix plc - Sponsored ADR
RNLXY Healthcare Health Information Services
Renalytix plc - Sponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $3.0 million, up 30.4% from fiscal 2024.
3.70
0.09
−2.37%
Follow RNLXY
Alert me
| Jun '17 | Jun '18 | Jun '19 | Dec '19 | Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | 2 | 2 | 4 |
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | 689.07 | 30.05 | 35.53 | 5.91 | 4.14 |
Altman Z-Score |
— | — | — | — | — | 91.05 | (3.61) | (9.10) | (38.03) | (45.27) |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | 9.18 | (9.81) | (25.63) | (89.52) | (106.67) |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | — | (2.79) | (4.36) | (11.47) | (5.13) |
P/Operating CF |
— | — | — | — | — | (216.40) | (6.30) | (14.00) | (1.81) | (1.51) |
P/B ratio |
— | — | — | — | — | 15.44 | 2.92 | 17.35 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | — | — | 15.44 | 2.92 | 17.35 | 0.00 | 0.00 |
EV/Sales |
— | — | — | — | — | 648.40 | 18.72 | 30.49 | 5.43 | 3.51 |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | (36.55) | (1.21) | (3.04) | (0.42) | (0.37) |
EV/FCF |
— | — | — | — | — | (34.69) | (1.19) | (2.99) | (0.41) | (0.36) |
Quick Ratio |
— | 0.19 | 8.00 | — | 4.34 | 9.31 | 3.59 | 1.58 | 0.52 | 0.92 |
Current Ratio |
— | 0.20 | 8.20 | — | 4.51 | 9.46 | 3.80 | 1.67 | 0.58 | 1.21 |
Net Debt/EBITDA |
— | (0.87) | 0.22 | — | 1.38 | 2.06 | 0.64 | 0.41 | 0.04 | (0.26) |
Debt/Assets |
0.00% | 492.28% | 0.00% | 0.00% | 0.65% | 0.00% | 15.34% | 24.57% | 53.94% | 136.07% |
Debt/Equity |
— | (1.26) | 0.00 | — | 0.01 | 0.00 | 0.25 | 1.08 | (0.55) | (1.19) |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.05 | 0.08 | 0.12 | 0.43 |
Operating CF/Net income |
— | 1.01 | 0.15 | — | 0.97 | 0.82 | 1.01 | 0.75 | 0.89 | 0.88 |
Capex/Depreciation |
— | — | (9.97) | — | (17.59) | (5.40) | (1.35) | 0.00 | 0.00 | — |
| — | (10.02%) | (1,031.32%) | — | (80.48%) | (79.49%) | (88.72%) | (242.76%) | 3,291.29% | 255.00% | |
| — | (921.96%) | (864.28%) | 0.00% | (64.38%) | (69.83%) | (70.39%) | (113.04%) | (173.34%) | (289.94%) | |
ROIC |
— | 0.00% | 0.00% | — | (363.82%) | (314.98%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 117.51% | (494.69%) | — | (74.54%) | (55.81%) | (131.82%) | (387.39%) | 697.00% | (1,700.00%) |
Average Days of Receivables |
— | — | — | — | 0.00 | 145.66 | 110.73 | 83.23 | 111.09 | 73.00 |
Research and Development Expense of Revenue |
— | — | 0.00% | — | 0.00% | 673.37% | 493.20% | 420.16% | 403.91% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | — | 0.00% | 1,574.71% | 1,330.77% | 842.26% | 1,334.78% | 613.33% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | — | 0.00% | 178.60% | 155.59% | 86.16% | 47.83% | 106.67% |
Graham Net Nets |
— | — | — | — | — | 0.05 | 0.28 | 0.03 | (0.66) | (0.17) |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 43.60 | — |
Earnings Yield |
— | — | — | — | — | (3.20%) | (50.73%) | (37.72%) | (324.37%) | (371.87%) |
Free Cash Flow Yield |
— | — | — | — | — | (2.71%) | (52.20%) | (28.74%) | (222.12%) | (235.86%) |
Revenue per Share |
— | 0.00 | 0.00 | — | 0.00 | 1.04 | 2.04 | 2.05 | 1.06 | 0.51 |
Operating CF per Share |
— | (0.01) | (7.23) | — | (8.06) | (19.86) | (31.52) | (20.58) | (13.75) | (3.07) |
Capex per Share |
— | 0.00 | (0.36) | — | (1.04) | (1.06) | (0.45) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (0.01) | (7.60) | — | (9.10) | (20.93) | (31.97) | (20.58) | (13.76) | (3.07) |
Cash per Share |
— | 0.00 | 10.80 | — | 12.08 | 45.55 | 28.36 | 14.90 | 2.49 | 0.65 |
Shareholders Equity per Share |
— | (0.01) | 10.05 | — | 13.47 | 49.98 | 21.00 | 4.21 | (3.62) | (1.20) |
Interest Debt per Share |
— | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.01) | 10.05 | — | 13.47 | 49.98 | 21.00 | 4.21 | (3.62) | (1.20) |
Free Cash Flow |
— | (0.41) | (6.46) | — | (10.75) | (29.92) | (46.59) | (34.08) | (29.80) | (17.90) |
Working Capital |
— | (0.35) | 8.27 | — | 11.55 | 59.73 | 32.98 | 10.75 | (5.00) | 1.00 |
Capital Expenditures |
— | — | (0.31) | — | (1.23) | (1.52) | (0.66) | — | 0.00 | — |
Net Current Asset Value |
— | (0.35) | 8.27 | — | 9.87 | 59.68 | 25.30 | 3.22 | (9.03) | (7.30) |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | — | 0.00 | 1.02 | 0.22 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | — | 0.11 | — | 0.04 | 0.11 | 0.36 | 0.49 | 12.50 | 0.00 |
Cash ROIC |
— | (241.98%) | (36.43%) | — | (35.46%) | (21.91%) | (58.51%) | (87.01%) | (1,614.52%) | (350.98%) |
Accounts Receivable Turnover |
— | — | — | — | 0.00 | 4.86 | 3.97 | 4.06 | 3.12 | 4.62 |
Accounts Payable Turnover |
— | — | 0.02 | — | 0.06 | 0.43 | 0.99 | 0.99 | 0.40 | 0.29 |
Inventory Turnover |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.20 |
Average Days of Payables |
— | — | 3,808.62 | — | 11,152.24 | 750.42 | 428.21 | 399.42 | 1,320.95 | 973.33 |
Days of Inventory on Hand |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 52.14 | 40.56 |
Average Receivables |
— | — | — | — | 0.35 | 0.31 | 0.75 | 0.84 | 0.74 | 0.65 |
Average Payables |
— | — | 1.27 | — | 1.27 | 1.99 | 2.11 | 2.70 | 5.27 | 6.20 |
Average Inventory |
— | — | — | — | — | — | — | — | — | 0.25 |
Average Assets |
— | 0.04 | 4.89 | 4.85 | 15.29 | 49.73 | 64.32 | 40.35 | 19.30 | 7.04 |
Average Common Equity |
— | 4.08 | 4.10 | — | 12.23 | 43.69 | 51.03 | 18.79 | (1.02) | (8.00) |
Columns are period end dates · fundamentals updated 26 Oct 2026